CASTLE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 32.99K shares, a 209.36% increase year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 28.49K shares, a 350.07% increase year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 87.46K shares, a 254.79% increase year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 4.00K shares, a 95.57% decline year-over-year.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 108.46K shares, a 20.18% decline from fiscal 2024.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 135.88K shares, a 89.97% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 71.53K shares, a 51.91% decline from fiscal 2022.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 148.74K shares, a 64.15% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 32.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 152.95K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 28.49K shares 10-Q · filed 2026-05-06 | 130.62K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 87.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 108.46K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 4.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 45.65K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | 10.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 132.03K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | 6.33K shares 10-Q · filed 2025-05-05 | 123.14K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | 24.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 135.88K shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 90.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | 132.99K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 1.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 46.27K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 19.07K shares 10-Q · filed 2024-05-02 | 60.00K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 21.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 71.53K shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 3.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 82.66K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 15.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 95.88K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 30.59K shares 10-Q · filed 2023-05-03 | 117.23K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 32.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 148.74K shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 16.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 168.22K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | 36.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 231.16K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | 62.10K shares 10-Q · filed 2022-05-09 | 306.51K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | 52.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 414.89K shares 10-K · filed 2023-02-28 |
| 2021-09-30 | 79.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 490.64K shares derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-06-30 | 112.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 539.92K shares derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-03-31 | 170.48K shares 10-Q · filed 2021-05-10 | 598.09K shares derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-12-31 | 128.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 460.21K shares 10-K · filed 2022-02-28 |
| 2020-09-30 | 129.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 337.69K shares derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | 170.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | |
| 2020-03-31 | 32.60K shares 10-Q · filed 2020-05-11 | |
| 2019-12-31 | 5.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 693.13K shares 10-K · filed 2021-03-11 |
| 2018-12-31 | 19.75K shares 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |